Accessibility StatementSkip Navigation NEW HAVEN, Conn., Nov. 4, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced that it has received The troriluzole clinical development program encompassed the first industry clinical trials to generate data showing therapeutic potential in patients with sp ...